CoSyne Therapeutics is a drug discovery company and spin-out from academic research at Imperial College London. It was founded in 2021 by experts in neuroscience, genetics and computational analysis.

CoSyne Therapeutics is using genetic computational systems analysis to develop next generation medicines at a faster rate, and for lower cost, compared to traditional methods.

The company’s first goal is to create a new class of drugs to treat the deadliest form of human brain cancer: Glioblastoma Multiforme.

The CoSyne Therapeutics platform has already identified dozens of novel vulnerabilities in GBM that can be targeted in a way that no other company or academic institution has done before.

Glioblastoma Multiforme (GBM)

“Brain tumours are awful things – they not only steal lives, they steal everything you are as a person.”

From a patient with glioblastoma multiforme.

Today, 95% of patients die within 5 years of receiving a diagnosis of GBM. There are approximately 26,400 new cases per-year in the US and Europe, including 2,500 per year in the UK. In addition to the terrible human cost to patients and families, GBM costs the UK economy approximately £1 billion per-year in NHS expenses, care needs and sick leave. To date, there are no effective treatments and the only drug currently in standard use (Temozolomide) provides a survival benefit of only 3 months


Our goal at CoSyne Therapeutics is to change this.